Cardiol Therapeutics Inc Class A Cash Flow-to-Debt Ratio
Cardiol Therapeutics Inc Class A cash flow-to-debt ratio. Cardiol Therapeutics Inc Class A (CRDL) has a Cash Flow-to-Debt Ratio of -0.91x as of December 2025, meaning its operating cash flow of CA$-5.23 Million could theoretically repay -1% of its total liabilities (CA$5.74 Million) in one year. See how financially flexible is Cardiol Therapeutics Inc Class A to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cardiol Therapeutics Inc Class A (2017–2025)
Cash flow-to-debt ratio of Cardiol Therapeutics Inc Class A from 2017 to 2025. Historical debt coverage capacity for Cardiol Therapeutics Inc Class A across 9 annual periods. Also explore Cardiol Therapeutics Inc Class A (CRDL) net asset momentum to track the company's year-over-year net asset growth rate.
Cardiol Therapeutics Inc Class A Cash Flow-to-Debt Ratio by Year (2017–2025)
Cardiol Therapeutics Inc Class A cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Cardiol Therapeutics Inc Class A. For the full cash flow conversion analysis, see cash efficiency ratio of Cardiol Therapeutics Inc Class A.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.15x | CA$-23.85 Million | CA$5.74 Million | ▼ -18.3% |
| 2024 | -3.51x | CA$-25.06 Million | CA$7.14 Million | ▼ -17.9% |
| 2023 | -2.98x | CA$-25.18 Million | CA$8.45 Million | ▼ -7.5% |
| 2022 | -2.77x | CA$-27.22 Million | CA$9.83 Million | ▼ -36.9% |
| 2021 | -2.02x | CA$-23.55 Million | CA$11.64 Million | ▲ +42.2% |
| 2020 | -3.50x | CA$-9.19 Million | CA$2.62 Million | ▲ +74.4% |
| 2019 | -13.70x | CA$-11.38 Million | CA$830.83K | ▼ -203.1% |
| 2018 | -4.52x | CA$-10.89 Million | CA$2.41 Million | ▼ -28.3% |
| 2017 | -3.52x | CA$-1.29 Million | CA$366.76K | — |